glp-1 obesity drug news october 2025 2024 was a record year for trials and is already poised to take over Outlook for Obesity in 2026:
Description
The volumetric finding is a hypothesis worth testing in a powered trial with volume change as a prespecified endpoint, not a demonstration that the drug protects brain tissue
nausea, vomiting, and abdominal discomfort), as well as other medical conditions that might delay gastric emptying such as Parkinsons disease, multiple sclerosis, amyloidosis, and scleroderma [19, 20]
Diabetes 64 , 715717 (2015)
Nutr Metab Cardiovasc Dis NMCD
Read Diabetic Why Traditional Diabetes Tests May Miss Early Disease: Understanding the New Era of Diabetes Detection Read Gastro Can Your Gut Really Act as a Second Brain
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin
